Ann: FIH Results Presented at EuroPCR & Simultaneous Publication, page-2

First in Human Results Presented at EuroPCR with Simultaneous Publication in EuroIntervention

Key Highlights:

1. The DurAVR™ Transcatheter Heart Valve (THV) First-in-Human Study demonstrated promising haemodynamic performance sustained to 1 year and restoration of nearnormal blood flow dynamics.

2. DurAVR™ THV demonstrated an outstanding safety profile: No mortality (all causes), no disabling stroke, no life-threatening bleeding, and no myocardial infarction were reported during any follow-up visits.

3. These encouraging preliminary First-in-Human study results will be further validated in an FDA-approved Early Feasibility Study (EFS) commencing soon


...nice confirmation for team AVR...